Literature DB >> 1425800

Serum levels of carboxyterminal propeptide of type I procollagen in healthy children from 1st year of life to adulthood and in metabolic bone diseases.

G Saggese1, S Bertelloni, G I Baroncelli, G Di Nero.   

Abstract

Type I collagen is the major component of bone matrix; circulating carboxyterminal propeptide of type I procollagen (P-I-CP) levels reflect type I collagen synthesis in tissues and may be an useful index to investigate bone metabolism. We measured P-I-CP by a new radioimmunoassay in 300 healthy children and adolescents and in 40 healthy adults to provide reference data for P-I-CP values. In addition, 79 patients with diagnosed disorders of phospho-calcium metabolism (rickets, vitamin D deficient and vitamin D resistant, hyperparathyroidism, hypo- and pseudo-hypoparathyroidism, osteopenia) were evaluated. In the healthy subjects, serum P-I-CP values were higher in children than in adults; variations of P-I-CP levels were observed according to age and sexual maturation: higher values were found in the first years of life and during pubertal development; pubertal increase reflects the different timing of pubertal development in the two sexes. P-I-CP levels were increased in primary hyperparathyroidism and reduced in diseases related to impaired secretion or action of parathyroid hormone. Higher P-I-CP levels were found in vitamin D deficient and vitamin D resistant rickets. P-I-CP was reduced in anorexia nervosa and during chronic glucocorticoid treatment while it was increased in thyrotoxic osteoporosis. In idiopathic juvenile osteoporosis, P-I-CP values ranged from reduced to increased values. We conclude that P-I-CP may represent an additional biochemical marker of bone metabolism. Since age-related variations are present, reference data for the various ages are need for clinical application of this assay.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1425800     DOI: 10.1007/bf01959087

Source DB:  PubMed          Journal:  Eur J Pediatr        ISSN: 0340-6199            Impact factor:   3.183


  20 in total

1.  [Osteocalcin in children].

Authors:  M Colle; A Ruffie
Journal:  Arch Fr Pediatr       Date:  1989-05

2.  Changes in plasma osteocalcin concentrations during treatment of rickets.

Authors:  F Greig; J Casas; S Castells
Journal:  J Pediatr       Date:  1989-05       Impact factor: 4.406

Review 3.  Glucocorticoid-induced osteoporosis: pathogenesis and management.

Authors:  B P Lukert; L G Raisz
Journal:  Ann Intern Med       Date:  1990-03-01       Impact factor: 25.391

4.  Evaluation of serum osteocalcin as an index of altered bone metabolism.

Authors:  K Kruse; U Kracht
Journal:  Eur J Pediatr       Date:  1986-04       Impact factor: 3.183

5.  Hypoparathyroidism and pseudohypoparathyroidism in childhood.

Authors:  D Daneman; S W Kooh; D Fraser
Journal:  Clin Endocrinol Metab       Date:  1982-03

6.  Measurement of bone mineral content of the lumbar spine by dual energy x-ray absorptiometry in normal children: correlations with growth parameters.

Authors:  C Glastre; P Braillon; L David; P Cochat; P J Meunier; P D Delmas
Journal:  J Clin Endocrinol Metab       Date:  1990-05       Impact factor: 5.958

7.  Serum osteocalcin in the treatment of inherited rickets with 1,25-dihydroxyvitamin D3.

Authors:  C M Gundberg; D E Cole; J B Lian; T M Reade; P M Gallop
Journal:  J Clin Endocrinol Metab       Date:  1983-05       Impact factor: 5.958

8.  Serum concentrations of the type I and III procollagen propeptides as biochemical markers of growth velocity in healthy infants and children and in children with growth disorders.

Authors:  P Trivedi; J Risteli; L Risteli; P C Hindmarsh; C G Brook; A P Mowat
Journal:  Pediatr Res       Date:  1991-09       Impact factor: 3.756

9.  Procollagen type I carboxy-terminal extension peptide in serum as a marker of collagen biosynthesis in bone. Correlation with Iliac bone formation rates and comparison with total alkaline phosphatase.

Authors:  A M Parfitt; L S Simon; A R Villanueva; S M Krane
Journal:  J Bone Miner Res       Date:  1987-10       Impact factor: 6.741

10.  Radioimmunoassay of the carboxyterminal propeptide of human type I procollagen.

Authors:  J Melkko; S Niemi; L Risteli; J Risteli
Journal:  Clin Chem       Date:  1990-07       Impact factor: 8.327

View more
  12 in total

1.  Sclerostin levels and bone turnover markers in adolescents with anorexia nervosa and healthy adolescent girls.

Authors:  Alexander T Faje; Pouneh K Fazeli; Debra K Katzman; Karen K Miller; Anne Breggia; Clifford J Rosen; Nara Mendes; Anne Klibanski; Madhusmita Misra
Journal:  Bone       Date:  2012-06-15       Impact factor: 4.398

2.  Markers of collagen metabolism and insulin-like growth factor binding protein-1 in term infants.

Authors:  T Hytinantti; E M Rutanen; M Turpeinen; R Sorva; S Andersson
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  2000-07       Impact factor: 5.747

3.  Low bone mineral density in anorexia nervosa: Treatments and challenges.

Authors:  Pouneh K Fazeli
Journal:  Clin Rev Bone Miner Metab       Date:  2019-04-15

4.  Fracture risk and areal bone mineral density in adolescent females with anorexia nervosa.

Authors:  Alexander T Faje; Pouneh K Fazeli; Karen K Miller; Debra K Katzman; Seda Ebrahimi; Hang Lee; Nara Mendes; Deirdre Snelgrove; Erinne Meenaghan; Madhusmita Misra; Anne Klibanski
Journal:  Int J Eat Disord       Date:  2014-01-15       Impact factor: 4.861

5.  Evaluation of bone loss and the serum markers of bone metabolism in patients with hyperparathyroidism.

Authors:  M Katagiri; T Ohtawa; M Fukunaga; T Harada
Journal:  Surg Today       Date:  1995       Impact factor: 2.549

6.  Effects of rhIGF-I administration on bone turnover during short-term fasting.

Authors:  S K Grinspoon; H B Baum; S Peterson; A Klibanski
Journal:  J Clin Invest       Date:  1995-08       Impact factor: 14.808

7.  Adolescent girls with anorexia nervosa have impaired cortical and trabecular microarchitecture and lower estimated bone strength at the distal radius.

Authors:  Alexander T Faje; Lamya Karim; Alex Taylor; Hang Lee; Karen K Miller; Nara Mendes; Erinne Meenaghan; Mark A Goldstein; Mary L Bouxsein; Madhusmita Misra; Anne Klibanski
Journal:  J Clin Endocrinol Metab       Date:  2013-03-18       Impact factor: 5.958

Review 8.  Effects of Anorexia Nervosa on Bone Metabolism.

Authors:  Pouneh K Fazeli; Anne Klibanski
Journal:  Endocr Rev       Date:  2018-12-01       Impact factor: 19.871

9.  Variable bone fragility associated with an Amish COL1A2 variant and a knock-in mouse model.

Authors:  Ethan Daley; Elizabeth A Streeten; John D Sorkin; Natalia Kuznetsova; Sue A Shapses; Stephanie M Carleton; Alan R Shuldiner; Joan C Marini; Charlotte L Phillips; Steven A Goldstein; Sergey Leikin; Daniel J McBride
Journal:  J Bone Miner Res       Date:  2010-02       Impact factor: 6.741

10.  Production of recombinant human procollagen type I C-terminal propeptide and establishment of a sandwich ELISA for quantification.

Authors:  Woo-Young Seo; Jeong-Ho Kim; Du-San Baek; Su-Jung Kim; Sujin Kang; Won Suk Yang; Ji-Ae Song; Moo-Seung Lee; Sunghoon Kim; Yong-Sung Kim
Journal:  Sci Rep       Date:  2017-11-21       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.